BridgeBio Pharma, Inc. and Oregon Health & Science University Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Diseases
PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Oregon Health & Science University (OHSU) in Portland, Oregon, to advance research and the development of investigational medicines for patients with genetically driven conditions.
“We feel privileged to have the opportunity to work with OHSU to focus on developing potential therapies for diseases with clear genetic drivers and severe unmet need,” said BridgeBio founder and CEO Neil Kumar, Ph.D. “OHSU was one of the first research institutions we connected with in the early days of BridgeBio, and we look forward to deepening our relationship through close collaboration with their scientists as we strive to help patients together.”
This arrangement builds on five years of informal collaborations between the two organizations. Under the agreement, the BridgeBio team will work closely with OHSU scientists and investigators to advance potential medicines for patients with genetically driven conditions, including cancers.
“BridgeBio’s approach to identifying and developing novel therapies allows them to interact with multiple investigators at OHSU who are studying a wide variety of diseases,” said OHSU Chief Research Officer and Executive Vice President Peter Barr-Gillespie, Ph.D. “We believe their expertise and infrastructure will help lead to the rapid development of new drugs. We see this collaboration as an important part of our efforts to bring OHSU innovations to clinical significance.”
BridgeBio collaborates with stand-out academic institutions, including OHSU, to support research around genetically driven conditions and is focused on rapidly translating findings into meaningful treatments for patients. Today BridgeBio also announced formal partnerships with Brown University, GlycoNet, The Lundquist Institute, Roswell Park Comprehensive Cancer Center, University of California, Davis and University of California, San Diego – for a total of 20 partnerships between BridgeBio and leading academic and research institutions to date. For a list of some of the institutions BridgeBio partners with, please visit Our Partners page.
With a diverse pipeline encompassing investigational therapies for rare diseases and genetically validated cancers, BridgeBio provides the insights and support needed to rapidly progress therapeutic research from labs to clinical development. BridgeBio intends to develop similar long-term partnerships based on trust, engagement, science and respect to support its mission of developing life-changing medicines for patients with genetically driven conditions as quickly and safely as possible.
About BridgeBio Pharma
BridgeBio is a
biopharmaceutical company founded to discover, create, test and
deliver transformative medicines to treat patients who suffer
from genetic diseases and cancers with clear genetic drivers.
BridgeBio’s pipeline of over 30 development programs ranges from
early science to advanced clinical trials and its commercial
organization is focused on delivering the company’s first
approved therapy. BridgeBio was founded in 2015 and its team of
experienced drug discoverers, developers and innovators are
committed to applying advances in genetic medicine to help
patients as quickly as possible. For more information visit bridgebiodev.wpengine.com.
BridgeBio Pharma Forward-Looking Statements
This press release contains forward-looking statements.
Statements we make in this press release may include statements
that are not historical facts and are considered forward-looking
within the meaning of Section 27A of the Securities Act of 1933,
as amended (the “Securities Act”), and Section 21E of the
Securities Exchange Act of 1934, as amended (the “Exchange
Act”), which are usually identified by the use of words such as
“anticipates,” “believes,” “estimates,” “expects,” “intends,”
“may,” “plans,” “projects,” “seeks,” “should,” “will,” and
variations of such words or similar expressions. We intend
these forward-looking statements to be covered by the safe
harbor provisions for forward-looking statements contained in
Section 27A of the Securities Act and Section 21E of the
Exchange Act and are making this statement for purposes of
complying with those safe harbor provisions. These
forward-looking statements, including statements relating to
expectations, plans, and prospects regarding our ability to
build on the significant advances being made in OHSU’s labs and
translate them into meaningful medicines for patients in need,
the success of current and future relationships with third-party
collaborators and academic partners, and the potential ability
of our product candidates to treat genetically driven diseases
and cancers with clear genetic drivers, reflect our current
views about our plans, intentions, expectations, strategies and
prospects, and are based on the information currently available
to us and on assumptions we have made and are neither forecasts,
promises nor guarantees. Although we believe that our plans,
intentions, expectations, strategies and prospects as reflected
in or suggested by these forward-looking statements are
reasonable, we can give no assurance that the plans, intentions,
expectations or strategies will be attained or achieved.
Furthermore, actual results may differ materially from those
described in the forward-looking statements and will be affected
by a number of risks, uncertainties and assumptions, including,
but not limited to, the success of our product candidates to
treat genetically driven diseases and cancers with clear genetic
drivers, the success of our collaboration with OHSU, as well as
those risks set forth in the Risk Factors section of BridgeBio
Pharma’s most recent Annual Report on Form 10-K and BridgeBio
Pharma’s other SEC filings. Moreover, we operate in a very
competitive and rapidly changing environment in which new risks
emerge from time to time. Except as required by applicable law,
we assume no obligation to update publicly any forward-looking
statements, whether as a result of new information, future
events or otherwise.
OHSU Contact:
Erik Robinson
[email protected]
(503) 494-8231
BridgeBio Contact:
Grace Rauh
BridgeBio
Pharma, Inc.
[email protected]
(917) 232-5478